Exagen Inc. Showcases Autoimmune Diagnostic Leadership at Q4 2025 Conferences
Dateline — CARLSBAD, Calif., November 11, 2025:Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Dateline — CARLSBAD, Calif., November 11, 2025:Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation...
